These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548 [TBL] [Abstract][Full Text] [Related]
24. Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience. Purshouse K; Protheroe AS Ther Adv Urol; 2019; 11():1756287218820804. PubMed ID: 30671143 [TBL] [Abstract][Full Text] [Related]
26. Systemic treatment for metastatic prostate cancer. Gravis G Asian J Urol; 2019 Apr; 6(2):162-168. PubMed ID: 31061802 [TBL] [Abstract][Full Text] [Related]
27. Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer. Elkon JM; Millett RL; Millado KF; Lin J Expert Opin Pharmacother; 2018 Apr; 19(5):507-509. PubMed ID: 29494266 [TBL] [Abstract][Full Text] [Related]
28. Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored? Thomas C; Baunacke M; Erb HHH; Füssel S; Erdmann K; Putz J; Borkowetz A Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008172 [TBL] [Abstract][Full Text] [Related]
29. [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy]. Ohlmann CH Urologe A; 2017 Nov; 56(11):1424-1429. PubMed ID: 28983763 [TBL] [Abstract][Full Text] [Related]
30. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676 [TBL] [Abstract][Full Text] [Related]
31. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374 [TBL] [Abstract][Full Text] [Related]
32. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790 [TBL] [Abstract][Full Text] [Related]
33. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059 [TBL] [Abstract][Full Text] [Related]
34. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332 [TBL] [Abstract][Full Text] [Related]
35. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Shenoy N; Kohli M Indian J Urol; 2016; 32(4):257-261. PubMed ID: 27843206 [TBL] [Abstract][Full Text] [Related]
36. Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer. Matsumura N; Fujita K; Nishimoto M; Minami T; Tahara H; Yoshimura K; Uemura H World J Urol; 2023 Aug; 41(8):2063-2068. PubMed ID: 36040500 [TBL] [Abstract][Full Text] [Related]